Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Clinical Cancer Research

• Publication date

  2009-03-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-08-1315PMID 19276288
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Final results of phase I and pharmacokinetic trial of SJG-136 administered on a daily x 3 schedule

  2008cited by this paper
• Enhanced repair of DNA interstrand crosslinking in ovarian cancer cells from patients following treatment with platinum-based chemotherapy

  2007cited by this paper
• A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias.

  2007cited by this paper
• Sequence-selective interaction of the minor-groove interstrand cross-linking agent SJG-136 with naked and cellular DNA: footprinting and enzyme inhibition studies.

  2005cited by this paper
• Fibroblast growth factor (FGF) 17 expression is up-regulated human prostate cancer and correlates to clinical prognosis

  2004cited by this paper
• SJG-136 (NSC 694501), a Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity

  2004cited by this paper
• The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases

  2004cited by this paper
• SJG-136 (NSC 694501), A Novel Rationally Designed DNA Minor Groove Interstrand Cross-Linking Agent with Potent and Broad Spectrum Antitumor Activity

  2004cited by this paper
• Methods in molecular medicine

  2004cited by this paper
• NK Cells and Polymorphonuclear Neutrophils Are Both Critical for IL-2-Induced Pulmonary Vascular Leak Syndrome1

  2004cited by this paper
• A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.

  2002cited by this paper
• Design, synthesis, and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient cross-linking ability and potent cytotoxicity.

  2001cited by this paper
• Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.

  2000cited by this paper
• Synthesis of a novel C2/C2′-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity

  1999cited by this paper
• Measurement of drug-induced DNA interstrand crosslinking using the single-cell gel electrophoresis (comet) assay.

  1999cited by this paper
• Nucleic acid targeting: therapeutic strategies for the 21st century.

  1999cited by this paper
• Cytotoxic drug resistance mechanisms

  1999cited by this paper
• Evidence for the involvement of Fas ligand and perforin in the induction of vascular leak syndrome.

  1998cited by this paper
• Accelerated titration designs for phase I clinical trials in oncology.

  1997cited by this paper
• Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4]benzodiazepines.

  1997cited by this paper
• Advances in the Study of Pyrrolo[2,1-c] [1,4]benzodiazepine (PBD) Antitumour Antibiotics

  1993cited by this paper
• A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.

  1993cited by this paper
• Molecular Aspects of Anticancer Drug/DNA Interactions

  1993cited by this paper
• Phase I trial of FK973: Description of a delayed vascular leak syndrome

  1991cited by this paper
• Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay.

  1990cited by this paper
• Heterogeneity in Radiation-Induced DNA Damage and Repair in Tumor and Normal Cells Measured Using the “Comet” Assay

  1990cited by this paper

• Synthesis of novel pyrrolobenzodiazepine (PBD) C1-substituted monomers and dimers with DNA-binding activity and cytotoxicity.

  2025cites this paper
• Alkyne modification of DNA cross-linking antitumor agent SJG-136 to monitor induced lesions in cells by click chemistry.

  2025cites this paper
• Pyrrolobenzodiazepine dimers for chemotherapy and antibody-drug conjugate applications.

  2025cites this paper
• Schiff bases and their metal complexes to target and overcome (multidrug) resistance in cancer.

  2024cites this paper
• Comparison of pyrrolobenzodiazepine dimer bis-imine versus mono-imine: DNA interstrand cross-linking, cytotoxicity, and antibody-drug conjugate efficacy and toxicity.

  2022cites this paper
• Risk Minimization of Antibody–Drug Conjugates in Oncology: A Review

  2021cites this paper
• Phase I Study of MEDI3726: A Prostate-Specific Membrane Antigen-Targeted Antibody–Drug Conjugate, in Patients with mCRPC after Failure of Abiraterone or Enzalutamide

  2021cites this paper
• Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.

  2021cites this paper
• Isolation, chemistry, and biology of pyrrolo[1,4]benzodiazepine natural products

  2021cites this paper
• Discovery and Chemical Development of Tesirine: An Antitumor Pyrrolobenzodiazepine Antibody-Drug Conjugate Drug-Linker

  2020cites this paper
• Benzodiazepine Derivatives from Marine-Derived Streptomyces

  2020cites this paper
• Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent

  2020cites this paper
• A first-in-human, phase 1, dose-escalation study of ABBV-176, an antibody-drug conjugate targeting the prolactin receptor, in patients with advanced solid tumors

  2020cites this paper
• Antibody-drug conjugates (ADCs) delivering pyrrolobenzodiazepine (PBD) dimers for cancer therapy

  2020cites this paper
• An FDA oncology analysis of toxicities associated with PBD-containing antibody-drug conjugates.

  2019cites this paper
• Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study

  2019cites this paper
• Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis

  2019cites this paper
• Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index

  2019cites this paper
• Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine

  2018cites this paper
• Improving the Safety Profile of ADCs

  2018cites this paper
• An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia

  2018cites this paper
• Antibody-Drug Conjugates for Cancer Treatment.

  2018cites this paper
• Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

  2018cites this paper
• Use of pyrrolobenzodiazepines and related covalent-binding DNA-interactive molecules as ADC payloads: Is mechanism related to systemic toxicity?

  2018cites this paper
• Sequence-selective binding of C8-conjugated pyrrolobenzodiazepines (PBDs) to DNA.

  2017cites this paper
• Targeting DNA Minor Groove by Hybrid Molecules as Anticancer Agents.

  2017cites this paper
• Entwicklung Pyrrolobenzodiazepin(PBD)‐haltiger Antikörper‐Wirkstoff‐Konjugate (ADCs) ausgehend von Anthramycin

  2017cites this paper
• Indole-based, Antiproliferative Agents Targeting Tubulin Polymerization.

  2016cites this paper
• From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)

  2016cites this paper
• Covalent Bonding of Pyrrolobenzodiazepines (PBDs) to Terminal Guanine Residues within Duplex and Hairpin DNA Fragments

  2016cites this paper
• A New Class of Antibody–Drug Conjugates with Potent DNA Alkylating Activity

  2016cites this paper
• Next‐Generation Antibody–Drug Conjugate Technologies

  2016cites this paper
• Development : translating 21 st-century science into the cancer medicines of tomorrow

  2015cites this paper
• Therapeutic Agents Based on DNA Sequence Specific Binding.

  2015cites this paper
• Effect of hairpin loop structure on reactivity, sequence preference and adduct orientation of a DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumour agent.

  2015cites this paper
• Activity of the DNA minor groove cross-linking agent SG2000 (SJG-136) against canine tumours

  2015cites this paper
• Cancer Research UK Centre for Drug Development: translating 21st-century science into the cancer medicines of tomorrow.

  2015cites this paper
• Evaluation of the Clastogenicity of SJG-136, A Novel Pyrrolobenzodiazepine DNA Interstrand Cross-linking Agent, in Comparison with Nitrogen Mustard (HN2)

  2015cites this paper
• Antibody-drug conjugates: an emerging concept in cancer therapy.

  2014cites this paper
• Pharmacokinetic and pharmacodynamic challenges of Antibody-Directed Enzyme Prodrug Therapy (ADEPT)

  2014cites this paper
• Damage γ-H 2 AX Pharmacodynamic Assay

  2014cites this paper
• Rational approaches, design strategies, structure activity relationship and mechanistic insights for anticancer hybrids.

  2014cites this paper
• Trevigen’s γ-H2AX Pharmacodynamic Assay

  2014cites this paper
• Azide based routes to tetrazolo and oxadiazolo derivatives of pyrrolobenzodiazepines and pyrrolobenzothiadiazepines

  2014cites this paper
• Tandem C-2 functionalization-intramolecular azide-alkyne 1,3-dipolar cycloaddition reaction: a convenient route to highly diversified 9H-benzo[b]pyrrolo[1,2-g][1,2,3]triazolo[1,5-d][1,4]diazepines.

  2014cites this paper
• Antikörper‐Wirkstoff‐Konjugate: ein neues Konzept in der Krebstherapie

  2014cites this paper
• Pyrrolobenzodiazepines (PBDs) Do Not Bind to DNA G-Quadruplexes

  2014cites this paper
• GC-targeted C8-linked pyrrolobenzodiazepine-biaryl conjugates with femtomolar in vitro cytotoxicity and in vivo antitumor activity in mouse models.

  2013cites this paper
• Efficient estimation of MMGBSA-based BEs for DNA and aromatic furan amidino derivatives

  2013cites this paper
• Can γH2AX be used to personalise cancer treatment?

  2013cites this paper
• Cancer Therapy : Clinical gH 2 AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents : Results from 2 Phase I Clinical Trials of SJG-136 ( SG 2000 )

  2013cites this paper
• γH2AX as a marker of DNA double strand breaks and genomic instability in human population studies.

  2013cites this paper
• Repair of DNA Interstrand Cross-links Produced by Cancer Chemotherapeutic Drugs

  2013cites this paper
• Use of the γ-H2AX assay to monitor DNA damage and repair in translational cancer research.

  2012cites this paper
• Small molecule drugs - optimizing DNA damaging agent-based therapeutics.

  2012cites this paper
• DNA interstrand cross-linking and in vivo antitumor activity of the extended pyrrolo[2,1-c][1,4]benzodiazepine dimer SG2057

  2012cites this paper
• γ-H2AX and other histone post-translational modifications in the clinic.

  2012cites this paper
• γ-H2AX Foci Formation as a Pharmacodynamic Marker of DNA Damage Produced by DNA Cross-Linking Agents: Results from 2 Phase I Clinical Trials of SJG-136 (SG2000)

  2012cites this paper
• Synthesis, anticancer activity and apoptosis inducing ability of bisindole linked pyrrolo[2,1-c][1,4]benzodiazepine conjugates.

  2012cites this paper
• DNA interstrand cross-linking agents and their chemotherapeutic potential.

  2012cites this paper
• Biosynthesis, synthesis, and biological activities of pyrrolobenzodiazepines

  2012cites this paper
• H2AX in DNA Damage Response

  2011cites this paper
• Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136, a Novel DNA Sequence Selective Minor Groove Cross-linking Agent, in Advanced Solid Tumors

  2011influential citation
• Mechanism of action: the unique pattern of bendamustine-induced cytotoxicity.

  2011cites this paper
• The development of pyrrolobenzodiazepines as antitumour agents

  2011cites this paper
• Observation of a single-stranded DNA/pyrrolobenzodiazepine adduct.

  2011cites this paper
• Pharmacokinetics, pharmacodynamics and metabolism of the dimeric pyrrolobenzodiazepine SJG-136 in rats

  2011cites this paper
• Effect of base sequence on the DNA cross-linking properties of pyrrolobenzodiazepine (PBD) dimers

  2011cites this paper
• The minor groove-binding agent ELB-21 forms multiple interstrand and intrastrand covalent cross-links with duplex DNA and displays potent bactericidal activity against methicillin-resistant Staphylococcus aureus

  2011cites this paper
• Nuclear magnetic resonance solution structures of inter- and intrastrand adducts of DNA cross-linker SJG-136.

  2011cites this paper
• Histone γH2AX and Poly(ADP-Ribose) as Clinical Pharmacodynamic Biomarkers

  2010cites this paper
• Structure-activity relationships of monomeric C2-aryl pyrrolo[2,1-c][1,4]benzodiazepine (PBD) antitumor agents.

  2010cites this paper
• SG2285, a novel C2-aryl-substituted pyrrolobenzodiazepine dimer prodrug that cross-links DNA and exerts highly potent antitumor activity.

  2010cites this paper
• A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors

  2010cites this paper
• Optimization of the Antitumor Activity of Sequence-specific Pyrrolobenzodiazepine Derivatives Based on their Affinity for ABC Transporters

  2010cites this paper
• Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents

  2009cites this paper
• H2AX: functional roles and potential applications

  2009cites this paper
• The pyrrolobenzodiazepine dimer SJG-136 forms sequence-dependent intrastrand DNA cross-links and monoalkylated adducts in addition to interstrand cross-links.

  2009cites this paper
• Harnessing competing endocytic pathways for overcoming the tumor-blood barrier: magnetic resonance imaging and near-infrared imaging of bifunctional contrast media.

  2009cites this paper
• Synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines (PBDs).

  1994cites this paper
• DRUGS THAT INTERACT IN THE DNA MINOR GROOVE

  year unknowncites this paper